Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

AGGRENOX 25 MG

ACETYLSALICYLIC ACID : 25 MG DIPYRIDAMOLE : 200 MG · DIN 02242119 · BOEHRINGER INGELHEIM (CANADA) LTD LTEE

Health Canada status: CANCELLED POST MARKET

What is AGGRENOX?

AGGRENOX 25 MG contains ACETYLSALICYLIC ACID : 25 MG DIPYRIDAMOLE : 200 MG. It is listed in the Health Canada Drug Product Database under DIN 02242119, held by BOEHRINGER INGELHEIM (CANADA) LTD LTEE, supplied as CAPSULE (IMMEDIATE AND EXTENDED RELEASE) for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 24-Feb-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What else is AGGRENOX called?

The same molecule, COMBINATIONS, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
EkyflogylLatinIceland
OTIPAXLatinCzechia

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

Product details and regulatory record

DIN02242119
Brand nameAGGRENOX
Generic / active ingredientACETYLSALICYLIC ACID : 25 MG DIPYRIDAMOLE : 200 MG
ManufacturerBOEHRINGER INGELHEIM (CANADA) LTD LTEE
Strength25 MG
Dosage formCAPSULE (IMMEDIATE AND EXTENDED RELEASE)
Route of administrationORAL
SchedulePrescription
ATC codeB01AC30 COMBINATIONS
AHFS class24:12.92
BiosimilarNo
Health Canada statusCANCELLED POST MARKET
Status date24-Feb-2020
Original market date2000-04-17 00:00:00

How is this product identified?

Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.

DIN (8-digit, as used in Nexara ordering)02242119
DIN (unpadded, as printed on some documents)2242119
Brand nameAGGRENOX
Active ingredient / INNACETYLSALICYLIC ACID : 25 MG DIPYRIDAMOLE : 200 MG
ATC codeB01AC30
ATC anatomical main groupB — Blood and blood-forming organs
ATC therapeutic subgroupB01
AHFS class24:12.92
Health Canada schedulePrescription
Biosimilar biologicNo
Market authorization holderBOEHRINGER INGELHEIM (CANADA) LTD LTEE

Health Canada approved product monograph (PDF)

Which pack is which?

Strength on the label25 MG
Dosage formCAPSULE (IMMEDIATE AND EXTENDED RELEASE)
RouteORAL

One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Confirm the pack and get a price

What can be used instead?

Other Canadian products sharing ATC code B01AC30 COMBINATIONS. 0 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
ASASANTINE CAP75 MGCAPSULEBOEHRINGER INGELHEIM (CANADA) LTD LTEECANCELLED POST MARKETDIN 00579327
TARO-DIPYRIDAMOLE/ ASA25 MGCAPSULE (IMMEDIATE AND EXTENDED RELEASE)TARO PHARMACEUTICALS INCCANCELLED POST MARKETDIN 02471051

Who else supplies COMBINATIONS worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. COMBINATIONS appears in 5 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How much does COMBINATIONS cost around the world?

COMBINATIONS is listed on 4 national price registers Nexara tracks, across 8 pack listings published on 4 different price bases. What each country publishes is set out below.

MarketWhat that country publishesBrands listedPack listingsAs of
Hungaryproducer price (ex-factory)5503 Sep 2026
Czechiamax producer price (ex-factory)1103 Sep 2026
Icelandmax wholesale1102 Sep 2026
Luxembourgreimbursement1105 Sep 2026

Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.

Ask Nexara for a landed Canadian price

Can this still be bought in Canada?

No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.

If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Health Canada Drug Product Database (DPD), DIN 02242119. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.